title: Renal transplantation in patients with systemic lupus erythematosus: increased risk of early graft loss.
abstract: The outcome of primary renal transplantation in 31 SLE patients was evaluated in relation to two contemporary controls per patient, matched for age, sex and immunosuppressive therapy. The proportion of living donors was one third in both groups. Patient survival did not differ, but graft survival at 6 and 12 months post transplantation was significantly reduced in SLE patients (p less than 0.001). When divided into groups using either azathioprine and steroids or combinations including cyclosporin A (14 and 17 SLE patients in each group), graft survival was significantly reduced for the azathioprine-treated SLE patients, 36% vs. 82% for their controls at one year. For cyclosporin-treated SLE patients, one-year graft survival was 59% vs. 85% for their controls, and 6 out of 17 grafts in the cyclosporin-treated group were lost within the first month vs. only 4 out of 34 controls. These differences were, however, not statistically different. Most failed grafts were lost from rejection, with a high proportion of acute vascular rejection, isolated or in combination with cellular rejection. There was no apparent association between rejection and HLA-matched or presence of HLA antibodies. Retransplantation was successful in 6 out of 7 cases. We conclude that SLE patients have an increased risk of early graft rejection, but that this may be overcome by more powerful immunosuppressive therapy.
authors.affiliation: Department of Nephrology, Sahlgrenska Hospital, Göteborg, Sweden.
authors.forename: G
authors.initials: G
authors.lastname: Nyberg
authors.forename: I
authors.initials: I
authors.lastname: Karlberg
authors.forename: C
authors.initials: C
authors.lastname: Svalander
authors.forename: L
authors.initials: L
authors.lastname: Hedman
authors.forename: I
authors.initials: I
authors.lastname: Blohmé
mesh_terms: D000293:Adolescent; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D003524:Cyclosporins / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology; D006684:HLA-DR Antigens / Q000032:analysis; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000503:physiopathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D003524:Cyclosporins; D006684:HLA-DR Antigens; D011239:Prednisolone; D001379:Azathioprine